Andreas Rimner, MD | Authors


Enhancing Benefit With Durvalumab in NSCLC After the PACIFIC Trial

December 03, 2019

Andreas Rimner, MD, gives an overview of his presentation titled, “Crossing the PACIFIC,” which he presented at the 2019 New York Lung Cancers Symposium. He evaluates some potential next steps for durvalumab (Imfinzi) following the practice-changing results from the PACIFIC trial.